(54) Title: REGULATING UTERINE MUSCULAR ACTIVITY

(72) Inventors: BEN-DAVID, Gal; 238 Hazait Street, 17940 Adi (IL). BEN-DAVID, Tamir; 55 Mivtza Kadesh Street, 69988 Tel Aviv (IL). CALDERON, Ilan; Bet Lechem Haglilit Street, 36007 Bet Lechem Haglilit (IL).

(74) Agent: KLEIN, David; 18 Menuha VeNahala Street, 76209 Rehovot (IL).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ).

[Continued on next page]
Published: — with international search report (Art. 21(3))

REGULATING UTERINE MUSCULAR ACTIVITY

FIELD OF THE INVENTION

The present invention relates generally to methods and systems for regulating uterine muscular activity based on EMG (electromyographic) measurement.

BACKGROUND OF THE INVENTION


However, despite knowing how to increase or reduce uterine activity, heretofore no one has described or hinted at increasing or reducing uterine activity (such as labor or preterm labor) by sensing uterine activity with controlled loop activity management, as will be described below in the description of embodiments of the invention. This has significant advantages over the prior art. For example, use of tocolytic drugs is expensive and may cause side effects. Use of electrical signals to inhibit or to intensify contraction may also have side effects. Use of contraction augmentation hormones may cause fetal stress. By sensing uterine activity with controlled loop activity management, the cost and possible side effects are reduced or eliminated.

SUMMARY OF THE INVENTION

The present invention is directed, among other things, to methods and systems for regulating uterine muscular activity based on EMG measurement, as is described more in detail hereinbelow. The muscular activity may be controlled by using drugs and/or electrical stimulation. The system can be implemented as a closed loop control system, wherein control decisions may be automatic or human based (physician decision).

There is thus provided in accordance with a non-limiting embodiment of the present invention a method and system for regulating uterine muscular activity including measuring uterine contraction with an electrical uterine monitor (EUM), and using sensed
measurements of the uterine contraction to regulate uterine muscular activity by comparing the sensed measurements to a desired level, wherein the difference between sensed and desired level is used to calculate the level of either manual or automatic application of a drug or electrical signal.

The EUM and processor may operate in a control loop with an electrical signal generator or drug delivery system for automatic application of the electrical signal or drug.

**BRIEF DESCRIPTION OF THE DRAWINGS**

The present invention will be understood and appreciated more fully from the following detailed description taken in conjunction with the appended drawings in which:

Fig. 1 is a simplified flow chart of a system/method for regulating uterine muscular activity (uterine contraction) based on EMG measurement, in accordance with a non-limiting embodiment of the present invention;

Fig. 2A is a simplified illustration of the system, in accordance with a non-limiting embodiment of the present invention, including an electrical uterine monitor (EUM) that operates with an electrical signal generator and/or drug delivery system;

Fig. 2B is a simplified illustration of the EUM as part of a uterine monitor (home or hospital/clinic system), cooperating with an electrical signal generator and/or drug delivery system, in accordance with a non-limiting embodiment of the present invention; and

Fig. 3 is a simplified illustration of an EUM, in accordance with a non-limiting embodiment of the present invention.

**DETAILED DESCRIPTION OF EMBODIMENTS**

Reference is now made to Fig. 1, which is a flow chart of a system/method for regulating uterine muscular activity (uterine contraction) based on EMG measurement, in accordance with a non-limiting embodiment of the present invention. In one non-limiting embodiment of the invention, measuring uterine contraction is done with an electrical uterine monitor (EUM), examples of which are described below with reference to Figs. 2A-2B and 3. The sensed measurements are used to regulate uterine muscular activity by continuously comparing the sensed measurements to a desired level. If the measured contraction amplitude is stronger than the desired level, a contraction reduction drug or pulse is applied. If the measured contraction amplitude is too weak, a contraction enhancer is applied. The difference between the desired and actual contraction levels may
be defined as an error signal. The level of control may be proportional to the error signal or may be a proportional/integral/differential (PID controller) of the error signal. Other control methods such as a bang-bang controller (on-off controller), also known as a hysteresis controller, may be employed.

Uterine activity may be increased or decreased. In accordance with a non-limiting embodiment of the invention, uterine activity may be increased using electrical stimulation (see Obstet Gynecol. 1989 Feb;73(2):286-90, "Transcutaneous Electrical Nerve Stimulation At Acupuncture Points In The Induction Of Uterine Contractions", Dunn PA, Rogers D, Halford K. Physiotherapy Department, Moorabbin Hospital, Melbourne, Australia; and Biol Reprod. 2008 Oct;79(4):633-7. Epub 2008 Jun 11, "Stimulation of fetal hypothalamus induces uterine contractions in pregnant rats at term", Endoh H, Fujioka T, Endo H, Inazuka Y, Furukawa S, Nakamura S. Department of Neuroscience and of Reproductive, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan); and/or oxytocin activity (see Lee HJ, Macbeth AH, Pagani JH, Young WS (June 2009). "Oxytocin: the Great Facilitator of Life". Progress in Neurobiology 88 (2): 127-51. doi:10.1016/j.neurobio.2009.04.001). For example, intravenous administration of dilute oxytocin is commonly used to increase uterine activity.


In one embodiment of the invention, during active labor the clinician (e.g., midwife or physician) regulates uterine activity to a level that will cause progress in cervix dilatation and fetal head station on one hand, but will not cause stress on the fetus
on the other hand. In this embodiment, the system uses closed loop control using the EUM as the uterine activity sensor and a dose of electrical stimulation/oxytocin as the control method. Note that there is only activity increase control but no activity reduction control.

Automatic application of drugs may be done by electronically operated drug dispensers (transdermal patches, invasive (needle) dispensers, intravenous dispensers and many others), which are in communication with the EUM sensor.

In another embodiment of the invention, if pre-term uterine activity appears, the system reduces uterine activity to a level that will not cause pre-term labor. By sensing uterine activity with controlled loop activity management, the system uses the minimum amount of drugs/signals as needed to reduce uterine activity to the desired level. Note that there is only activity decrease control but no activity increase control.

In another embodiment of the invention, the system is used to treat non-pregnant women who experience spontaneous contractions.

Uterine contractions can occur in non-pregnant women during menstruation, which cause significant pain (see Aguilar, H. N.; Xiao, S.; Knoll, A. H.; Yuan, X. (2010). "Physiological pathways and molecular mechanisms regulating uterine contractility". Human Reproduction Update 16 (6): 725-744. doi:10.1093/humupd/dmq016. JSTOR 1306737. PMID 20551073). The uterine activity sensor detects the level of uterine contraction and the effect of a tocolytics drug on the contraction. Such uterine contraction measurement can help minimize or eliminate drug/signal usage, while reducing uterine activity to the desired level. Note that there is only activity decrease control but no activity increase control.

In another set up, such a sensor can be used for the diagnosis of pain (not just control of the pain), resulting from uterine contractions, specifically during menstruation. The sensed uterine activity is compared to known (previously measured or otherwise stored) uterine contractions due to menstruation, and a diagnosis can be made if the sensed uterine activity is indicative of menstrual uterine contraction.

In another embodiment of the invention, the system is used to treat non-pregnant women who experience induced contractions.

Uterine contractions can occur in non-pregnant women when the uterus is stimulated by a medical operation. One example is during IVF embryo transfer (see "Uterine contractions at the time of embryo transfer alter pregnancy rates after in-vitro
fertilization", R Fanchin, C Righini, F Olivennes, S Taylor, D de Ziegler and R Frydman, Department of Obstetrics and Gynaecology and Reproductive Endocrinology, Hopital Antoine Beclere, Clamart, France, Oxford Journals, Human Reproduction, Volume 13, Issue 7, Pp. 1968-1974). The objective is to use as little drugs/electrical inhibitor signals as needed to reduce uterine activity to the desired level (or even prevent contraction completely). This may be a single stage (phase) or a two-stage (or multi-stage) protocol. In the two-stage protocol, during the first stage, a test is made by applying the stimulation (inserting a catheter) without actual medical effect. The uterine response is recorded using the sensor (EUM). During the second phase, during actual medical treatment, the control tocolytic is applied, based on the first stage and/or real time analysis of uterine activity. In another setup uterine activities are measured and regulated after IVF embryo transfer for a period of up to few weeks to detect unwanted uterine contraction.

Reference is now made to Figs. 2A-2B, which illustrate one example of an EUM 10, which is described in US Patent 7447542. Briefly, US Patent 7447542 describes an improved system for three-dimensional monitoring (e.g., measuring, imaging and displaying) of myographic uterine activity. The system includes an electromyogram (EMG) system that senses electromyographic activity generated in a muscle, one or more position sensors, and a processor in communication with the EMG system and the position sensors. The processor processes data of the EMG system and the three-dimensional position information from the position sensors to provide an output of electromyographic activity in the three dimensional space, providing contraction intensity data as a function of time. As opposed to prior art intra-uterine pressure catheters, the EUM measurement is non-invasive. Another known technology, the toco-dynamometer, does not provide contraction intensity information.

EUM 10 (or EUM electrode 10) includes one or more uterine electrical activity sensors 12 mounted on a substrate 14, which is placed on the abdominal wall of the pregnant or non-pregnant woman. Substrate 14 may be in the form of a "tree" 16, with the sensors 12 mounted on a portion of "branches" 36 that extend from a "trunk" 38. One or more fiduciary marks 18 are provided to enable repeatable positioning of EUM 10, i.e., positioning EUM 10 at the same place on the abdomen at each use. Uterine electrical activity sensors 12 may include electromyogram (EMG) electrodes, such as but not limited to, nine EMG surface recording Ag/AgCl electrodes and an optional reference electrode.
Substrate 14 may be formed with non-symmetrical identification elements 40, such as cutouts or other markings (e.g., particular geometric shapes, such as triangles or hexagons, placed at pre-determined positions), in order to prevent incorrect mounting of the device on the abdomen.

The three-dimensional position and orientation of each uterine activity sensor 12 is known as described above using an off the shelf position sensor or using the known structure of the electrode. Processor 34 processes electrical signals of the uterine activity sensors 12 and the three-dimensional position and orientation to provide an output that comprises electromyographic activity data as a mathematical function of the three-dimensional position and orientation of the uterine activity sensor 12. This provides contraction intensity data as a function of time, by using, for example, the integral of electromyographic activity over all the uterus volume.

EUM electrode 10 is generally intended for single use only, staying functional for at least 18 hours (relatively long labor time), for example. However, the invention is not limited to such a device and the invention can be used for multiple uses as well.

EUM electrode 10 is able to identify individual sensors 12 and their positions. For example, the sensors 12 may be marked in numbers left to right, top to bottom, and/or may be color-coded and/or may be each uniquely shaped, for easy visual identification. Additionally or alternatively, each sensor 12 may be assigned a unique position code that processor 34 identifies, so that the position of each sensor 12 is known.

In Fig. 2B, EUM 10 is provided as part of a uterine monitor (home or hospital/clinic) system. EUM 10 is attached to the woman in the confines of her home. EUM 10 senses or monitors data, performs local control of contractions, and/or communicates the data to a remote site (e.g., a website) via processor 34, also referred to as EUM unit 34 (which may be worn around the neck or mounted on another part of the body) to perform a remote regulation of the contractions.

In both Figs. 2A and 2B, the sensors 12 and processor 34 of EUM 10 cooperate with an electrical signal generator 55 (e.g., electrodes, electrical stimulating apparatus, electrical interference signals, and the like) and/or drug delivery system 57 (e.g., intravenous, hypodermic needle, transdermal patch, and others) for administrating electrical stimulation or interference and/or drugs, as described above.

Reference is now made to Fig. 3. For non-pregnant women, the uterus is small, so instead of the embodiment of Figs. 2A-2B, an electrode array 50 is used to sense the
electrical activity of the uterus. The electrode array 50 includes one or more uterine electrical activity sensors 52 mounted on a substrate 54 (similar to electrical activity sensors 12 and substrate 14 of Figs. 2A-2B). Substrate 54 may be in the form of a strap which may be wrapped around the torso or other portion of the woman. Since the patient is not pregnant, electrodes may be placed both on the back and the abdomen, for example.

Since during some operations, e.g., IVF embryo transfer, the clinician uses ultrasound modality to navigate the catheter, the electrode array design may have an area with no electrodes to allow access to the ultrasound probe.

It is appreciated that various features of the invention which are, for clarity, described in the contexts of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
CLAIMS

What is claimed is:

1. A method for regulating uterine muscular activity comprising:
   measuring uterine contraction with an electrical uterine monitor (EUM) (10); and
   characterised by using sensed measurements of the uterine contraction to regulate
   uterine muscular activity by comparing the sensed measurements to a desired level,
   wherein the difference between sensed and desired level is used to calculate the level of
   either manual or automatic application of a drug or electrical signal.

2. The method according to claim 1, wherein said uterine muscular activity is
   increased.

3. The method according to claim 1, wherein said uterine muscular activity is
   decreased.

4. The method according to claim 2, wherein said uterine muscular activity is
   increased using electrical stimulation.

5. The method according to claim 2, wherein said uterine muscular activity is
   increased by administering oxytocin.

6. The method according to claim 3, wherein said uterine muscular activity is
   decreased by administering a tocolytic.

7. The method according to claim 3, wherein said uterine muscular activity is
   decreased by using interference electrical signals.

8. The method according to claim 1, comprising regulating the uterine muscular
   activity to a level that causes progress in cervix dilatation and fetal head station, but does
   not cause stress on a fetus.

9. The method according to claim 1, comprising regulating the uterine muscular
   activity to a level that does not cause pre-term labor.

10. The method according to claim 1, comprising regulating the uterine muscular
    activity to treat a non-pregnant woman who experiences contractions.

11. The method according to claim 10, wherein said non-pregnant woman experiences
    contractions during menstruation.

12. The method according to claim 10, wherein said non-pregnant woman experiences
    contractions during an IVF procedure.

13. A system for regulating uterine muscular activity comprising:

   an electrical uterine monitor (EUM) (10) for measuring uterine contraction; and
characterised by a processor (34) operative to use sensed measurements of the uterine contraction to regulate uterine muscular activity by comparing the sensed measurements to a desired level, wherein the difference between sensed and desired level is used to calculate the level of either manual or automatic application of a drug or electrical signal.

14. The system according to claim 13, wherein said EUM (10) and said processor (34) operate in a control loop with an electrical signal generator (55) or drug delivery system (57) for automatic application of the electrical signal or drug.

15. The system according to claim 13, wherein said uterine muscular activity is increased.

16. The system according to claim 13, wherein said uterine muscular activity is decreased.
SENSE UTERINE MUSCULAR ACTIVITY (USE EUM)

USE SENSED MEASUREMENTS TO REGULATE UTERINE MUSCULAR ACTIVITY BY COMPARING SENSED MEASUREMENTS WITH DESIRED LEVEL

CONTRACTION TOO STRONG?

Y

APPLY CONTRACTION REDUCING DRUG/STIMULATION

N

CONTRACTION TOO WEAK?

N

Y

APPLY CONTRACTION ENHANCING DRUG/STIMULATION

FIG. 1
**INTERNATIONAL SEARCH REPORT**

International application No

PCT/US2013/0490 11

A. CLASSIFICATION OF SUBJECT MATTER

<table>
<thead>
<tr>
<th>Inv.</th>
<th>A61N 1/36</th>
<th>A61M5/00</th>
</tr>
</thead>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61N A51M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronics database consulted during the International search (name of database and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5 447 526 A (KARSDON JEFFREY [US]) 5 September 1995 (1995-09-05) abstract; figures 9, 10</td>
<td>13-16</td>
</tr>
<tr>
<td>A</td>
<td>DE 20 004 014220 UI (GI ESELER HEINZ [DE]) 5 January 2005 (2005-01-05) the whole document</td>
<td>13-16</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:
  *"A" document defining the general state of the art which is not considered to be of particular relevance
  *"E" earlier application or patent but published on or after the international filing date
  *"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *"O" document referring to an oral disclosure, use, exhibition or other means
  *"P" document published prior to the international filing date but later than the priority date claimed

**Date of the actual completion of the international search**

26 September 2013

**Date of mailing of the international search report**

09/10/2013

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax. (+31-70) 340-3018

Authorized officer:

Wetzig, Thomas
INTERNATIONAL SEARCH REPORT

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [ ] Claims Nos.: 1-12
   because they relate to subject matter not required to be searched by this Authority, namely:

   Rule 39.1 (iv) PCT - Method for treatment of the human or animal body by therapy

2. [ ] Claims Nos.: (as applicable)
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claims Nos.:  (as applicable)
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 64(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of additional fees.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers:

   a) those claims that were searchable (Continuation of first sheet (2)) (April 2005)

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.

[ ] The additional search fees were accompanied by the applicant’s protest but the applicable protest exceeded the time limit specified in the invitation.

[ ] No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 5447526 A</td>
<td>05-09-1995</td>
<td>US 5447526 A</td>
<td>05-09-1995</td>
</tr>
<tr>
<td>CA 2531650 AI</td>
<td>20-01-2005</td>
<td>EP 1643900 Al</td>
<td>12-04-2006</td>
</tr>
<tr>
<td>WO 2005004717 Al</td>
<td>20-01-2005</td>
<td>DE 202004014220 UI</td>
<td>05-01-2005</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (April 2005)